CN120051493A - 抗ccr8抗体及其用途 - Google Patents

抗ccr8抗体及其用途 Download PDF

Info

Publication number
CN120051493A
CN120051493A CN202380073161.0A CN202380073161A CN120051493A CN 120051493 A CN120051493 A CN 120051493A CN 202380073161 A CN202380073161 A CN 202380073161A CN 120051493 A CN120051493 A CN 120051493A
Authority
CN
China
Prior art keywords
seq
sequence
amino acid
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380073161.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·T·布鲁索
G·沃金肖
C·维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of CN120051493A publication Critical patent/CN120051493A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380073161.0A 2022-08-19 2023-08-18 抗ccr8抗体及其用途 Pending CN120051493A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263399483P 2022-08-19 2022-08-19
US63/399,483 2022-08-19
PCT/US2023/072462 WO2024040216A2 (fr) 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations

Publications (1)

Publication Number Publication Date
CN120051493A true CN120051493A (zh) 2025-05-27

Family

ID=88020873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380073161.0A Pending CN120051493A (zh) 2022-08-19 2023-08-18 抗ccr8抗体及其用途

Country Status (7)

Country Link
EP (1) EP4573126A2 (fr)
JP (1) JP2025527535A (fr)
KR (1) KR20250052418A (fr)
CN (1) CN120051493A (fr)
AU (1) AU2023325323A1 (fr)
CA (1) CA3265264A1 (fr)
WO (1) WO2024040216A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024248037A1 (fr) 2023-05-30 2024-12-05
WO2025145207A1 (fr) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Polythérapie d'inhibiteur de kras et d'agent de déplétion des treg

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
CA2348292A1 (fr) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Preparation contenant une proteine betacelluline
DK1638941T3 (da) 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
CA2541651C (fr) 2003-10-22 2011-05-24 Keck Graduate Institute Methodes de synthese de polypeptides heteromultimeres dans une levure, utilisant une strategie de conjugaison d'haploides
WO2006076288A2 (fr) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Constructions d'adn pour l'expression a long terme d'adn nu en injection intravasculaire
CA3160204A1 (fr) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anticorps anti-ccr8 et leurs utilisations
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
WO2022136647A1 (fr) * 2020-12-24 2022-06-30 Oncurious Nv Liants ccr8 humains
KR20240046533A (ko) 2021-08-20 2024-04-09 하이파이바이오 인코퍼레이티드 항-ccr8 항체 및 그것의 용도

Also Published As

Publication number Publication date
JP2025527535A (ja) 2025-08-22
EP4573126A2 (fr) 2025-06-25
AU2023325323A1 (en) 2025-03-27
KR20250052418A (ko) 2025-04-18
WO2024040216A2 (fr) 2024-02-22
WO2024040216A3 (fr) 2024-04-11
CA3265264A1 (fr) 2024-02-22

Similar Documents

Publication Publication Date Title
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
EP3344658B1 (fr) Anticoprs anti tigit (human t-cell immunoglobulin and itim domain)
JP2023088925A (ja) Ｐｓｇｌ－１アンタゴニスト及びその使用
CN105636986A (zh) 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
CN120051493A (zh) 抗ccr8抗体及其用途
TWI867138B (zh) 抗tnfr2抗體及其用途
CN117980336A (zh) 抗tnfr2抗体及其用途
CN117279954A (zh) 抗人cxcr5抗体及其用途
HK40119929A (zh) 抗ccr8抗体及其用途
US20260028407A1 (en) Modified anti-galectin-9 antibody and uses thereof
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40120080A (zh) 经修饰的抗半乳凝素-9抗体及其用途
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40119929

Country of ref document: HK

SE01 Entry into force of request for substantive examination